Colinz Laboratories Q1 Results FY27: Net Profit at Rs 2 Cr for June 2026 Quarter
- July 31, 2026
- Posted by: Ankit Jaiswal
- Category: News
Colinz Laboratories Q1 results FY27: Revenue Rs 1 Cr. Net profit Rs 2 Cr. Standalone basis. Stock at Rs 80 (+1.52%) on 30 July 2026.
Key Takeaways
- Colinz Laboratories’s revenue for the June 2026 quarter came in at Rs 1 Cr, declined 20.76% year on year from Rs 1 Cr.
- Colinz Laboratories came in at a standalone net profit of Rs 2 Cr, up 1914.43% from Rs 0.12 Cr in Q1 FY26.
- Gross profit was reported at Rs 0.02 Cr for the quarter.
- The percentage profit growth this quarter is inflated by a very small year-ago base and should be read with that context.
- The stock traded at Rs 80 on 30 July 2026, up 1.52% during the session.
If you are searching for Colinz Laboratories Q1 results FY27, here is the direct answer: Colinz Laboratories reported standalone revenue of Rs 1 Cr and a net profit of Rs 2 Cr for the quarter ended 30 June 2026, declined 20.76% year on year from Rs 1 Cr. The rest of this article expands on that answer with the full revenue and profit breakdown, what changed compared with Q1 FY26, how the stock reacted, and what to watch next, so you do not need to piece it together from multiple sources.
Prepared by Kunal Singla, Associate Director at Univest, this review of the Colinz Laboratories Q1 results FY27 is based on figures disclosed in the company’s exchange filing for the June 2026 quarter.
Click Here – Get Free Investment Predictions
Colinz Laboratories Q1 Results FY27: Key Numbers at a Glance
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 1 Cr | Rs 1 Cr | -20.76% |
| Gross Profit | Rs 0.02 Cr | Rs 0.1 Cr | -75.80% |
| Net Profit | Rs 2 Cr | Rs 0.12 Cr | 1914.43% |
All figures in the Colinz Laboratories Q1 results FY27 table above are on a standalone basis for the quarter ended 30 June 2026, compared with Q1 FY26. This is the core data set behind the Colinz Laboratories Q1 results FY27 search.
Colinz Laboratories Q1 Results FY27: What Drove Revenue
Revenue for Colinz Laboratories in Q1 FY27 declined 20.76% from Rs 1 Cr to Rs 1 Cr, against Rs 1 Cr in Q1 FY26. Anyone comparing Colinz Laboratories against its own past performance should treat this as the base number: a company in the pharmaceutical formulations space, this pace of growth reflects demand and pricing trends specific to that segment during the June 2026 quarter.
Notably, revenue actually declined even as profit rose in the Colinz Laboratories Q1 results FY27, meaning the profit improvement this quarter came from cost control or a favourable one-off rather than topline growth. This combination is worth flagging directly for investors comparing companies purely on headline profit growth.
Colinz Laboratories Q1 Results FY27: Profitability Breakdown
Colinz Laboratories came in at a standalone net profit of Rs 2 Cr, up 1914.43% from Rs 0.12 Cr in Q1 FY26 in Q1 FY27. Gross profit for the quarter was Rs 0.02 Cr, a change of -75.80% from Rs 0.1 Cr in Q1 FY26.
Because the year-ago net profit base was very small, at just Rs 0.12 Cr, the 1914% headline growth rate in the Colinz Laboratories Q1 results FY27 looks more dramatic than the absolute rupee change. Investors should anchor to the Rs 2 Cr absolute profit figure rather than the percentage alone.
Stock Price Reaction to the Colinz Laboratories Q1 Results FY27
Colinz Laboratories shares traded at Rs 80 on 30 July 2026, up 1.52% during the session. If your search intent is specifically about the stock reaction rather than the raw numbers, this is the figure that answers it: the market’s verdict weighed the revenue and profit results together, alongside broader market conditions on the day.
Talk to a SEBI Registered Investment Adviser Before You Invest
What the Colinz Laboratories Q1 Results FY27 Mean for Investors
The Colinz Laboratories Q1 results FY27 give investors three concrete data points: a revenue base of Rs 1 Cr, a net profit of Rs 2 Cr, and a year-on-year growth trajectory that either confirms or challenges the investment thesis for the stock. None of these numbers should be read in isolation from the detailed exchange filing, segment disclosures and management commentary that typically accompany results.
Comparing this quarter with peers in the pharmaceutical formulations space is also useful context. A company can post strong absolute growth and still lag its peer set, or post modest growth that is nonetheless best-in-class for its sector, so relative positioning matters as much as the standalone numbers in the Colinz Laboratories Q1 results FY27. Investors who track a basket of names in the same industry will typically get a clearer read on whether this quarter reflects a company-specific story or a broader sector trend.
Business Context Behind the Colinz Laboratories Q1 Results FY27
Colinz Laboratories operates in the pharmaceutical formulations space, where demand cycles, input costs and competitive intensity all shape quarterly performance. The Colinz Laboratories Q1 results FY27 should be read against these sector-level dynamics rather than as a standalone number, since the same growth rate can carry very different implications depending on the underlying industry conditions.
Quarterly results are unaudited and subject to limited review, so any restatements or exceptional items disclosed in the notes to the Colinz Laboratories Q1 results FY27 can shift how the reported profit should be interpreted. Reading the full exchange filing alongside this summary remains the most reliable way to form a complete view, particularly for line items such as other income, exceptional items and tax adjustments that do not always show up in a headline summary.
Key Things to Watch After the Colinz Laboratories Q1 Results FY27
- Sequential trend: Whether the momentum in the Colinz Laboratories Q1 results FY27 carries into the September 2026 quarter or proves to be a one-off.
- Management commentary: Guidance on demand, margins and capital allocation for the rest of FY27.
- Sector conditions: Developments in the pharmaceutical formulations space that could influence input costs, pricing power or competitive intensity.
- Corporate actions: Any dividend, capex or strategic announcements accompanying the results that signal management’s confidence in the outlook.
- Balance sheet health: Debt levels, working capital trends and cash flow generation, which together determine how much flexibility Colinz Laboratories has to fund future growth.
Download the Univest iOS App or Univest Android App to track quarterly results, live prices and research updates in one place.
Conclusion
The Colinz Laboratories Q1 results FY27 show standalone revenue of Rs 1 Cr and a net profit of Rs 2 Cr for the quarter ended 30 June 2026. The quarter’s profit delivery keeps the near-term earnings narrative broadly intact. As Kunal Singla notes, investors should track the next few quarterly prints and management commentary before drawing firm conclusions, and consult a SEBI registered investment adviser before acting on these results.
Disclaimer: This article is for educational and informational purposes only and should not be considered investment advice. Revenue, gross profit and net profit figures are sourced from the company’s exchange filings for the quarter ended 30 June 2026. Stock market investments are subject to risks. Please consult a SEBI registered investment adviser before making any investment decision. Univest Research Analyst SEBI Registration No. INH000013776.
FAQs on Colinz Laboratories Q1 Results FY27
What was Colinz Laboratories’s revenue in Q1 results FY27?
Ans. Colinz Laboratories’s revenue in Q1 results FY27 was Rs 1 Cr, declined 20.76% year on year from Rs 1 Cr.
Did Colinz Laboratories make a profit or loss in Q1 FY27?
Ans. Colinz Laboratories reported a net profit of Rs 2 Cr in Q1 results FY27 on a standalone basis for the quarter ended 30 June 2026.
What was Colinz Laboratories’s gross profit in Q1 FY27?
Ans. Colinz Laboratories’s gross profit in Q1 results FY27 was Rs 0.02 Cr, against Rs 0.1 Cr in Q1 FY26.
When were the Colinz Laboratories Q1 results FY27 announced?
Ans. The Colinz Laboratories Q1 results FY27 were announced on 30 July 2026, covering the quarter ended 30 June 2026.
Did Colinz Laboratories shares go up or down after the Q1 results FY27?
Ans. Colinz Laboratories shares traded at Rs 80 on 30 July 2026, up 1.52% following the Q1 results FY27.
Were the Colinz Laboratories Q1 results FY27 consolidated or standalone?
Ans. The Colinz Laboratories Q1 results FY27 are on a standalone basis, as reported in the company’s exchange filing for the June 2026 quarter.
What should investors watch after Colinz Laboratories’s Q1 results FY27?
Ans. Investors should watch the sequential trend into the September quarter, management commentary, sector-level conditions in the pharmaceutical formulations space, and any corporate action announcements.
Are the Colinz Laboratories Q1 results FY27 a buy signal?
Ans. Quarterly results are a data point, not a recommendation. Investors should assess valuations, earnings quality and their own risk profile, and consult a SEBI registered investment adviser before investing.
